This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS
Abelacimab for prevention of venous thromboembolism. N Engl J Med 2021; 385: 609-617.
Published: 9th December 2021
Authors: Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Buller HR et al.
A single dose of this factor XI inhibitor in patients undergoing knee surgery reduced the rate of postoperative venous thromboembolism (P<0.001) compared to standard Enoxaparin thromboprophylaxis, without increasing the risk of bleeding.Pubmed Link
You may also be interested in
Intermittent pneumatic compression in addition to standard prophylaxis of postoperative venous thromboembolism in extremely high-risk patients (IPC SUPER): a randomized controlled trial. Ann Surg 2021; 274: 63-69.
Authors: Lobastov K, Sautina E, Alencheva E, Bargandzhiya A, Schastlivtsev I, Barinov V et al.
Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382: 1599-1607
Authors: Agnelli G, Becattini C, Meyer G, Munoz A, Huisman MV, Connors JM et al.
Adjunctive intermittent pneumatic compression for venous thromboprophylaxis. N Engl J Med 2019; 380: 1305-1315.
Authors: Arabi YM, Al-Hameed F, Burns KEA, Mehta S, Alsolamy SJ, Alshahrani MS et al.
Extended versus conventional thromboprophylaxis after major abdominal and pelvic surgery: Systematic review and meta-analysis of randomized clinical trials. Surgery 2018; 164: 1234-1240.
Authors: Rausa E, Kelly ME, Asti E, Aiolfi A, Bonitta G, Winter DC et al.
Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019; 380: 720-728.
Authors: Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T et al.
Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380: 711-719.
Authors: Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A et al.
Thromboembolism incidence and prophylaxis use after gastrectomy among Korean patients with gastric adenocarcinoma. The PROTECTOR randomized clinical trial. JAMA Surg 2018; 153: 939-946.
Authors: Jung YJ, Seo HS, Park CH, Jeon HM, Kim J-I, Yim HW et al.
Venous thromboembolism incidence and prophylaxis use after gastrectomy among Korean patients with gastric adenocarcinoma. The PROTECTOR randomized clinical trial. JAMA Surg 2018; 153: 939-946.
Authors: Jung YJ, Seo HS, Park CY, Jeon HM, Kim J-I, Yim HW et al.
Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematol 2018; 1: e25-e33.
Authors: Ten Cate-Hoek AJ, Amin EE, Bouman AC, Meijer K, Tick LW, Middeldorp S et al.
Randomized double-blinded study comparing medical treatment versus iliac vein stenting in chronic venous disease. J Vasc Surg Venous Lymphatic 2018; 6: 183-191.
Authors: Rossi FH, Kambara AM, Izukawa NM, Rodrugues TO, Rossi CB, Sousa AG et al.
Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615-624.
Authors: Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al.
Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 2017; 377: 2240-2252.
Authors: Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ et al.